Scolaris Content Display Scolaris Content Display

Levonorgestrel‐releasing intrauterine system for endometrial hyperplasia

This is not the most recent version

References

Additional references

Abu Hashim 2015

Abu Hashim H, Ghayaty E, Rakhawy ME. Levonorgestrel‐releasing intrauterine system vs oral progestins for non‐atypical endometrial hyperplasia: a systematic review and metaanalysis of randomised trials. American Journal of Obstetrics & Gynecology 2015;213(4):469‐78.

Anastasiadis 2000

Anastasiadis PG, Skaphida PG, Koutlaki NG, Galazios GC, Tsikouras PN, Liberis VA. Descriptive epidemiology of endometrial hyperplasia in patients with abnormal uterine bleeding. European Journal of Gynaecological Oncology 2000;21(2):131‐4.

Crosbie 2014

Crosbie E, Morrison J. Editorial: The emerging epidemic of endometrial cancer: Time to take action. www.cochranelibrary.com/editorial/10.1002/14651858.ED000095 (accessed 29th July 2015). [DOI: 10.1002/14651858.CD000095]

Dominick 2015

Dominick S, Hickey M, Chin J, Su IH. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. Cochrane Database of Systematic Reviews 2015, Issue 12. [DOI: 10.1002/14651858.CD007245.pub3]

Ferlay 2017

Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. Cancer Incidence and Mortality Worldwide. IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency on Research on Cancer; 2017. Available from: http://globocan.iarc.fr, accessed on 2nd May 2017. Vol. GLOBOCAN 2012 v1.1.

Gallos 2010

Gallos ID, Shehmar M, Thangaratinam S, Papapostolou TK, Coomarasamy AMD, Gupta JK. Oral progestogens vs levonorgestrel‐releasing intrauterine system for endometrial hyperplasia: a systematic review and metaanalysis. American Journal of Obstetrics & Gynecology 2010;203(6):547.e1‐10.

Gallos 2013

Gallos ID, Krishan P, Shehmar M, Ganesan R, Gupta JK. LNG‐IUS versus oral progestogen treatment for endometrial hyperplasia: a long‐term comparative cohort study. Human Reproduction 2013;28(11):2966‐71. [DOI: 10.1093/humrep/det320]

Giede 2008

Giede KC, Yen TW, Chibbar R, Pierson RA. Significance of concurrent endometrial cancer in women with a preoperative diagnosis of atypical endometrial hyperplasia. Journal of Obstetrics and Gynaecology Canada 2008;30(10):896‐901.

GRADEpro GDT 2014 [Computer program]

GRADE Working Group, McMaster University. GRADEpro GDT. Version accessed 1 September 2016. Hamilton (ON): GRADE Working Group, McMaster University, 2014.

Guttinger 2007

Guttinger A, Critchley H O. Endometrial effects of intrauterine levonorgestrel. Contraception 2007;75(6 Suppl):S93‐8. [DOI: 10.1016/j.contraception.2007.01.015]

Higgins 2011

Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. The Cochrane Collaboration, Available from handbook.cochrane.org.

Kurman 1985

Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long‐term study of "untreated" hyperplasia in 170 patients. Cancer 1985;56(2):403‐12.

Kurman 2011

Kurman RJ, Hedrick‐Ellenson L, Ronnett BM, editor(s). Blaustein's Pathology of the Female Genital Tract. 6th Edition. New York: Springer, 2011.

Lacey 2010

Lacey JV, Sherman ME, Rush BB, Ronnett BM, Ioffe OB, Duggan MA, et al. Absolute risk of endometrial carcinoma during 20‐year follow‐up among women with endometrial hyperplasia. Journal of Clinical Oncology 2010;28(5):788‐92. [DOI: 10.1200/JCO.2009.24.1315]

Landrum 2012

Landrum L, Zuna R, Walker JL. Endometrial hyperplasia, estrogen therapy, and the prevention of endometrial cancer. In: Saia P, Creasman W editor(s). Clinical Gynecologic Oncology. 8th Edition. Philadelphia: Elsevier/Saunders, 2012:121‐40.

Lefebre 2011

Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.

Lethaby 2015

Lethaby A, Munawar H, Rishworth JR, Rees MC. Progesterone or progestogen‐releasing intrauterine systems for heavy menstrual bleeding. Cochrane Database of Systematic Reviews 2015, Issue 4. [DOI: 10.1002/14651858.CD002126.pub3]

Luo 2013

Luo L, Luo B, Zheng Y, Zhang H, Li J, Sidell N. Levonorgestrel‐releasing intrauterine system for atypical endometrial hyperplasia. Cochrane Database of Systematic Reviews 2013, Issue 6. [DOI: 10.1002/14651858.CD009458.pub2]

Morelli 2013

Morelli M, Di Cello A, Venturella R, Mocciaro R, D'Alessandro P, Zullo F. Efficacy of the levonorgestrel intrauterine system (LNG‐IUS) in the prevention of the atypical endometrial hyperplasia and endometrial cancer: retrospective data from selected obese menopausal symptomatic women. Gynecological Endocrinology 2013;29(2):156‐9. [DOI: 10.3109/09513590.2012.730579]

NICE 2016

National Institute for Health and Care Excellence. Heavy menstrual bleeding: assessment and management. Clinical guideline [CG44]. Published date: January 2007. Last updated: August 2016. www.nice.org.uk/guidance/cg44 (accessed 30th July 2015).

Pfizer 2016

Pfizer New Zealand Ltd. Provera Medroxyprogesterone acetate data sheet October 2016. http://www.medsafe.govt.nz/profs/Datasheet/p/Proveratab.pdf (accessed 28th April 2017).

RCOG 2016

Gallos ID, Alazzam M, Clark TJ, Faraj R, Rosenthal AN, Smith PP, Gupta JK. Management of Endometrial Hyperplasia. Green‐top Guideline No. 67. www.rcog.org.uk/globalassets/documents/guidelines/green‐top‐guidelines/gtg_67_endometrial_hyperplasia.pdf (accessed 30th July 2015).

RevMan 2014 [Computer program]

Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.

Sangkomkamhang 2013

Sangkomkamhang US, Lumbiganon P, Laopaiboon M, Mol BWJ. Progestogens or progestogen‐releasing intrauterine systems for uterine fibroids. Cochrane Database of Systematic Reviews 2013, Issue 2. [DOI: 10.1002/14651858.CD008994.pub2]

Scully 1994

Scully RE, Bonfiglio TA, Kurman RJ, Silverberg SG, Wilkinson EJ. Histological typing of female genital tract tumours. In: Sobin LH editor(s). International Histological Classification of Tumours. 2nd Edition. Berlin, Heidelberg: Springer‐Verlag, 1994. [DOI: 10.1007/978‐3‐642‐85014‐1]

Singh 2013

Singh S, Best C, Dunn S, Leyland N, Wolfman WL, Clinical Practice ‐ Gynaecology Committee, et al. SOGC Clinical Practice Guideline: abnormal uterine bleeding in pre‐menopausal women. Journal of Obstetrics and Gyynaecology Canada 2013;35(5 Suppl 1):S1‐S28.

Trimble 2006

Trimble CL, Kauderer J, Zaino R, Silverberg S, Lim PC, Burke JJ, et al. Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer 2006;106(4):812‐9.

Vilos 2011

Vilos GA, Marks J, Tureanu V, Abu‐Rafea B, Vilos AG. The levonorgestrel intrauterine system Is an effective treatment in selected obese women with abnormal uterine bleeding. Journal of Minimally Invasive Gynecology 2011;18(1):75‐80. [DOI: 10.1016/j.jmig.2010.09.013]

Wise 2016

Wise M, Jordan V, Lagas A, Showell M, Wong N, Lensen S, et al. Obesity and endometrial hyperplasia and cancer in premenopausal women: a systematic review. American Journal of Obstetrics & Gynaecology2016; Vol. 214, issue 6:689.e1‐e17. [DOI: 10.1016/j.ajog.2016.01.175]

Zaino 2014

Zaino R, Carinelli SG, Ellenson LH. Tumours of the uterine corpus: epithelial tumours and precursors. In: Kurman RJ, Carcangiu ML, Herrington CS, Young RH editor(s). WHO Classification of Tumours of Female Reproductive Organs. 4th Edition. Lyon: WHO Press, 2014:125‐6.